ABOUT US
2001.01
Holy Stone Healthcare Co., Ltd. is registered and established in Taipei
2005.02
Signed an agency distribution agreement with Cellestis Limited (Australia), obtaining the exclusive distribution rights for the Latent Tuberculosis Infection Test Tube Kit product in Taiwan
2007.04
Established a European subsidiary, MDT Int’l S.A. (Geneva, Switzerland), responsible for the development and sales of Class III medical devices in the EU region
2008.02
The subsidiary MDT Int’l S.A. receives ISO 13485:2003 certification and CE certification for the product SportVis
2009.02
The subsidiary MDT Int’l S.A. obtained CE certification for RenehaVis
2013.05
The subsidiary MDT Int’l S.A. has obtained CE certification for the rectal infusion solution named TRUD
2013.12
Holy Stone Healthcare Co., Ltd. is listed on the Emerging Market of the Taiwan Over-the-Counter Securities Exchange (stock code: 4194)
2015.05
The new medical device GAF, developed in collaboration with MDT's supplier, is a gel ointment for the healing of anal fissure wounds and has obtained CE certification in the EU
2017.10
Signed an agency distribution agreement with MediWound Ltd., obtaining the exclusive distribution rights for the "MediWound" debridement gel product (NexoBrid®) in Taiwan
2023.06
BOD of Holy Stone Healthcare Co., Ltd. resolved the split-off and capital reduction of the businesses for agency distribution in Taiwan and long-term equity investment
2023.12
Holy Young BioMedical Co., Ltd. is registered and established in Taipei
2025.01
Signs Partnership Agreement with Lundoch Diagnostics AB (Sweden) to Promote AI-driven Diabetes Risk Prediction IVD Products (LDcoder) in Taiwan